Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07231419 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 5 of 75 sitesv15
  2. Trial sites expanded: 66 → 75 locationsv14
  3. Study sites: 65 to 66v13
  4. Study sites: 63 to 65v12
  5. Trial sites expanded: 55 → 63 locationsv11
  6. Trial sites expanded: 29 → 55 locationsv10
  7. Trial sites expanded: 25 → 29 locationsv9
  8. Study sites: 23 to 25v8
  9. Study sites: 21 to 23v7
  10. Study sites: 18 to 21v6
  11. Study sites: 13 to 18v5
  12. Study sites: 8 to 13v4
  13. Study sites: 3 to 8v3
  14. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Start date changed from estimate of Nov 17, 2025 to Nov 21, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Start date changed from estimate of Nov 17, 2025 to Nov 21, 2025
  15. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Trial Details
NCT Number NCT07231419
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 734 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov